Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Interventions in WNT signaling to induce cardiomyocyte proliferation: crosstalk with other pathways.

Blankesteijn WM.

Mol Pharmacol. 2019 Nov 22. pii: mol.119.118018. doi: 10.1124/mol.119.118018. [Epub ahead of print]

2.

Urocortin2 Gene Transfer Improves Heart Function in Aged Mice.

Giamouridis D, Gao MH, Lai NC, Guo T, Miyanohara A, Blankesteijn WM, Biessen EAL, Hammond HK.

Mol Ther. 2019 Oct 18. pii: S1525-0016(19)30457-5. doi: 10.1016/j.ymthe.2019.10.003. [Epub ahead of print]

PMID:
31676153
3.

The Beneficial Effects of UM206 on Wound Healing After Myocardial Infarction in Mice Are Lost in Follow-Up Experiments.

Daskalopoulos EP, Hermans KCM, Debets J, Strzelecka A, Leenders P, Vervoort-Peters L, Janssen BJA, Blankesteijn WM.

Front Cardiovasc Med. 2019 Sep 18;6:118. doi: 10.3389/fcvm.2019.00118. eCollection 2019.

4.

Corrigendum to: 'Sutured and sutureless repair of postinfarction left ventricular free-wall rupture: a systematic review' [Eur J Cardiothorac Surg; doi:10.1093/ejcts/ezz101].

Matteucci M, Fina D, Jiritano F, Blankesteijn WM, Raffa GM, Kowalewski M, Beghi C, Lorusso R.

Eur J Cardiothorac Surg. 2019 Nov 1;56(5):1023. doi: 10.1093/ejcts/ezz150. No abstract available.

PMID:
31065669
5.

Sutured and sutureless repair of postinfarction left ventricular free-wall rupture: a systematic review.

Matteucci M, Fina D, Jiritano F, Blankesteijn WM, Raffa GM, Kowalewski M, Beghi C, Lorusso R.

Eur J Cardiothorac Surg. 2019 Nov 1;56(5):840-848. doi: 10.1093/ejcts/ezz101.

PMID:
30938415
6.

Treatment strategies for post-infarction left ventricular free-wall rupture.

Matteucci M, Fina D, Jiritano F, Meani P, Blankesteijn WM, Raffa GM, Kowaleski M, Heuts S, Beghi C, Maessen J, Lorusso R.

Eur Heart J Acute Cardiovasc Care. 2019 Jun;8(4):379-387. doi: 10.1177/2048872619840876. Epub 2019 Apr 1.

7.

Wnt/β-Catenin Inhibitor Dickkopf 1.

Reinhold S, Blankesteijn WM.

Arterioscler Thromb Vasc Biol. 2019 Feb;39(2):121-123. doi: 10.1161/ATVBAHA.118.312144. No abstract available.

PMID:
30673348
8.

Hypertension-induced cognitive impairment: insights from prolonged angiotensin II infusion in mice.

Foulquier S, Namsolleck P, Van Hagen BT, Milanova I, Post MJ, Blankesteijn WM, Rutten BP, Prickaerts J, Van Oostenbrugge RJ, Unger T.

Hypertens Res. 2018 Oct;41(10):817-827. doi: 10.1038/s41440-018-0090-9. Epub 2018 Aug 17.

PMID:
30120397
9.

Effects of Urocortin 2 Versus Urocortin 3 Gene Transfer on Left Ventricular Function and Glucose Disposal.

Giamouridis D, Gao MH, Lai NC, Tan Z, Kim YC, Guo T, Miyanohara A, Blankesteijn WM, Biessen E, Hammond HK.

JACC Basic Transl Sci. 2018 May 30;3(2):249-264. doi: 10.1016/j.jacbts.2017.12.004. eCollection 2018 Apr.

10.

The Therapeutic Potential of Blocking Galectin-3 Expression in Acute Myocardial Infarction and Mitigating Inflammation of Infarct Region: A Clinical Outcome-Based Translational Study.

Mosleh W, Chaudhari MR, Sonkawade S, Mahajan S, Khalil C, Frodey K, Shah T, Dahal S, Karki R, Katkar R, Blankesteijn WM, Page B, Pokharel S, Kim M, Sharma UC.

Biomark Insights. 2018 May 3;13:1177271918771969. doi: 10.1177/1177271918771969. eCollection 2018.

11.

WNT Signaling in Cardiac and Vascular Disease.

Foulquier S, Daskalopoulos EP, Lluri G, Hermans KCM, Deb A, Blankesteijn WM.

Pharmacol Rev. 2018 Jan;70(1):68-141. doi: 10.1124/pr.117.013896. Review.

12.

Intermittent pacing therapy favorably modulates infarct remodeling.

Uitterdijk A, Springeling T, Hermans KCM, Merkus D, de Beer VJ, Gorsse-Bakker C, Mokelke E, Daskalopoulos EP, Wielopolski PA, Cleutjens JPM, Blankesteijn WM, Prinzen FW, van der Giessen WJ, van Geuns RM, Duncker DJ.

Basic Res Cardiol. 2017 May;112(3):28. doi: 10.1007/s00395-017-0616-3. Epub 2017 Apr 6.

13.

Myocardial and Serum Galectin-3 Expression Dynamics Marks Post-Myocardial Infarction Cardiac Remodelling.

Sharma UC, Mosleh W, Chaudhari MR, Katkar R, Weil B, Evelo C, Cimato TR, Pokharel S, Blankesteijn WM, Suzuki G.

Heart Lung Circ. 2017 Jul;26(7):736-745. doi: 10.1016/j.hlc.2016.11.007. Epub 2016 Dec 19.

14.

Wnt Signaling in Cardiac Remodeling and Heart Failure.

Stylianidis V, Hermans KCM, Blankesteijn WM.

Handb Exp Pharmacol. 2017;243:371-393. doi: 10.1007/164_2016_56. Review.

PMID:
27838851
15.

CXCL10 Is a Circulating Inflammatory Marker in Patients with Advanced Heart Failure: a Pilot Study.

Altara R, Manca M, Hessel MH, Gu Y, van Vark LC, Akkerhuis KM, Staessen JA, Struijker-Boudier HA, Booz GW, Blankesteijn WM.

J Cardiovasc Transl Res. 2016 Aug;9(4):302-14. doi: 10.1007/s12265-016-9703-3. Epub 2016 Jun 6.

PMID:
27271043
16.

The Janus face of myofibroblasts in the remodeling heart.

Hermans KC, Daskalopoulos EP, Blankesteijn WM.

J Mol Cell Cardiol. 2016 Feb;91:35-41. doi: 10.1016/j.yjmcc.2015.11.017. Epub 2015 Dec 12. Review. No abstract available.

PMID:
26690324
17.

Left Ventricular Dysfunction and CXCR3 Ligands in Hypertension: From Animal Experiments to a Population-Based Pilot Study.

Altara R, Gu YM, Struijker-Boudier HA, Thijs L, Staessen JA, Blankesteijn WM.

PLoS One. 2015 Oct 27;10(10):e0141394. doi: 10.1371/journal.pone.0141394. eCollection 2015.

18.

Attenuation of post-infarction remodeling in rats by sustained myocardial growth hormone administration.

Daskalopoulos EP, Vilaeti AD, Barka E, Mantzouratou P, Kouroupis D, Kontonika M, Tourmousoglou C, Papalois A, Pantos C, Blankesteijn WM, Agathopoulos S, Kolettis TM.

Growth Factors. 2015;33(4):250-8. doi: 10.3109/08977194.2015.1072527. Epub 2015 Aug 12.

PMID:
26290214
19.

Attenuation of post-infarction remodeling in rats by sustained myocardial growth hormone administration.

Daskalopoulos EP, Vilaeti AD, Barka E, Mantzouratou P, Kouroupis D, Kontonika M, Tourmousoglou C, Papalois A, Pantos C, Blankesteijn WM, Agathopoulos S, Kolettis TM.

Growth Factors. 2015 Aug 12:1-9. [Epub ahead of print]

PMID:
26267792
20.

Wnt Signaling in Cardiac Disease.

Hermans KC, Blankesteijn WM.

Compr Physiol. 2015 Jul 1;5(3):1183-209. doi: 10.1002/cphy.c140060. Review.

PMID:
26140714
21.

Improving membrane based multiplex immunoassays for semi-quantitative detection of multiple cytokines in a single sample.

Altara R, Manca M, Hessel MH, Janssen BJ, Struijker-Boudier HH, Hermans RJ, Blankesteijn WM.

BMC Biotechnol. 2014 Jul 15;14:63. doi: 10.1186/1472-6750-14-63.

22.

Targeting Wnt signaling to improve wound healing after myocardial infarction.

Daskalopoulos EP, Janssen BJ, Blankesteijn WM.

Methods Mol Biol. 2013;1037:355-80. doi: 10.1007/978-1-62703-505-7_21. Review.

PMID:
24029947
23.

Cardiac (myo)fibroblast: Novel strategies for its targeting following myocardial infarction.

Daskalopoulos EP, Hermans KC, Blankesteijn WM.

Curr Pharm Des. 2014;20(12):1987-2002. Review.

PMID:
23844732
24.

Interventions in Wnt signaling as a novel therapeutic approach to improve myocardial infarct healing.

Hermans KC, Daskalopoulos EP, Blankesteijn WM.

Fibrogenesis Tissue Repair. 2012 Sep 11;5(1):16. doi: 10.1186/1755-1536-5-16.

25.

Myofibroblasts in the infarct area: concepts and challenges.

Daskalopoulos EP, Janssen BJ, Blankesteijn WM.

Microsc Microanal. 2012 Feb;18(1):35-49. doi: 10.1017/S143192761101227X. Epub 2012 Jan 4. Review.

PMID:
22214878
26.

Oxidation of CaMKII determines the cardiotoxic effects of aldosterone.

He BJ, Joiner ML, Singh MV, Luczak ED, Swaminathan PD, Koval OM, Kutschke W, Allamargot C, Yang J, Guan X, Zimmerman K, Grumbach IM, Weiss RM, Spitz DR, Sigmund CD, Blankesteijn WM, Heymans S, Mohler PJ, Anderson ME.

Nat Med. 2011 Nov 13;17(12):1610-8. doi: 10.1038/nm.2506.

27.

Blocking of frizzled signaling with a homologous peptide fragment of wnt3a/wnt5a reduces infarct expansion and prevents the development of heart failure after myocardial infarction.

Laeremans H, Hackeng TM, van Zandvoort MA, Thijssen VL, Janssen BJ, Ottenheijm HC, Smits JF, Blankesteijn WM.

Circulation. 2011 Oct 11;124(15):1626-35. doi: 10.1161/CIRCULATIONAHA.110.976969. Epub 2011 Sep 19.

PMID:
21931076
28.

The Wnt/Frizzled pathway as a therapeutic target for cardiac hypertrophy: where do we stand?

ter Horst P, Smits JF, Blankesteijn WM.

Acta Physiol (Oxf). 2012 Jan;204(1):110-7. doi: 10.1111/j.1748-1716.2011.02309.x. Epub 2011 May 27. Review.

PMID:
21624093
29.

Discovery of novel small molecule activators of β-catenin signaling.

Verkaar F, van der Stelt M, Blankesteijn WM, van der Doelen AA, Zaman GJ.

PLoS One. 2011 Apr 29;6(4):e19185. doi: 10.1371/journal.pone.0019185.

30.

Inhibition of Wnt/β-catenin signaling by p38 MAP kinase inhibitors is explained by cross-reactivity with casein kinase Iδ/ɛ.

Verkaar F, van der Doelen AA, Smits JF, Blankesteijn WM, Zaman GJ.

Chem Biol. 2011 Apr 22;18(4):485-94. doi: 10.1016/j.chembiol.2011.01.015.

31.

Wnt/frizzled signalling modulates the migration and differentiation of immortalized cardiac fibroblasts.

Laeremans H, Rensen SS, Ottenheijm HC, Smits JF, Blankesteijn WM.

Cardiovasc Res. 2010 Aug 1;87(3):514-23. doi: 10.1093/cvr/cvq067. Epub 2010 Feb 26.

PMID:
20189955
32.

Myocardial remodeling after infarction: the role of myofibroblasts.

van den Borne SW, Diez J, Blankesteijn WM, Verjans J, Hofstra L, Narula J.

Nat Rev Cardiol. 2010 Jan;7(1):30-7. doi: 10.1038/nrcardio.2009.199. Epub 2009 Dec 1. Review.

PMID:
19949426
33.

beta-Galactosidase enzyme fragment complementation for the measurement of Wnt/beta-catenin signaling.

Verkaar F, Blankesteijn WM, Smits JF, Zaman GJ.

FASEB J. 2010 Apr;24(4):1205-17. doi: 10.1096/fj.09-141671. Epub 2009 Nov 25.

PMID:
19940259
34.

Mouse strain determines the outcome of wound healing after myocardial infarction.

van den Borne SW, van de Schans VA, Strzelecka AE, Vervoort-Peters HT, Lijnen PM, Cleutjens JP, Smits JF, Daemen MJ, Janssen BJ, Blankesteijn WM.

Cardiovasc Res. 2009 Nov 1;84(2):273-82. doi: 10.1093/cvr/cvp207. Epub 2009 Jun 19.

PMID:
19542177
35.

Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling.

van den Borne SW, Isobe S, Zandbergen HR, Li P, Petrov A, Wong ND, Fujimoto S, Fujimoto A, Lovhaug D, Smits JF, Daemen MJ, Blankesteijn WM, Reutelingsperger C, Zannad F, Narula N, Vannan MA, Pitt B, Hofstra L, Narula J.

JACC Cardiovasc Imaging. 2009 Feb;2(2):187-98. doi: 10.1016/j.jcmg.2008.11.011.

36.

Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction.

van den Borne SW, Isobe S, Verjans JW, Petrov A, Lovhaug D, Li P, Zandbergen HR, Ni Y, Frederik P, Zhou J, Arbo B, Rogstad A, Cuthbertson A, Chettibi S, Reutelingsperger C, Blankesteijn WM, Smits JF, Daemen MJ, Zannad F, Vannan MA, Narula N, Pitt B, Hofstra L, Narula J.

J Am Coll Cardiol. 2008 Dec 9;52(24):2017-28. doi: 10.1016/j.jacc.2008.07.067.

37.

Stably overexpressed human Frizzled-2 signals through the beta-catenin pathway and does not activate Ca2+-mobilization in Human Embryonic Kidney 293 cells.

Verkaar F, van Rosmalen JW, Smits JF, Blankesteijn WM, Zaman GJ.

Cell Signal. 2009 Jan;21(1):22-33. doi: 10.1016/j.cellsig.2008.09.008. Epub 2008 Sep 25.

PMID:
18929644
38.

Diffusion tensor imaging of left ventricular remodeling in response to myocardial infarction in the mouse.

Strijkers GJ, Bouts A, Blankesteijn WM, Peeters TH, Vilanova A, van Prooijen MC, Sanders HM, Heijman E, Nicolay K.

NMR Biomed. 2009 Feb;22(2):182-90. doi: 10.1002/nbm.1299.

PMID:
18780284
39.

G protein-independent cell-based assays for drug discovery on seven-transmembrane receptors.

Verkaar F, van Rosmalen JW, Blomenröhr M, van Koppen CJ, Blankesteijn WM, Smits JF, Zaman GJ.

Biotechnol Annu Rev. 2008;14:253-74. doi: 10.1016/S1387-2656(08)00010-0. Review.

PMID:
18606367
40.

Defective intercellular adhesion complex in myocardium predisposes to infarct rupture in humans.

van den Borne SW, Narula J, Voncken JW, Lijnen PM, Vervoort-Peters HT, Dahlmans VE, Smits JF, Daemen MJ, Blankesteijn WM.

J Am Coll Cardiol. 2008 Jun 3;51(22):2184-92. doi: 10.1016/j.jacc.2008.02.056.

41.

The Wnt/frizzled pathway in cardiovascular development and disease: friend or foe?

van de Schans VA, Smits JF, Blankesteijn WM.

Eur J Pharmacol. 2008 May 13;585(2-3):338-45. doi: 10.1016/j.ejphar.2008.02.093. Epub 2008 Mar 18. Review.

PMID:
18417121
42.

Increased matrix metalloproteinase-8 and -9 activity in patients with infarct rupture after myocardial infarction.

van den Borne SW, Cleutjens JP, Hanemaaijer R, Creemers EE, Smits JF, Daemen MJ, Blankesteijn WM.

Cardiovasc Pathol. 2009 Jan-Feb;18(1):37-43. doi: 10.1016/j.carpath.2007.12.012. Epub 2008 Mar 4.

PMID:
18402833
43.

The Wnt/frizzled/GSK-3 beta pathway: a novel therapeutic target for cardiac hypertrophy.

Blankesteijn WM, van de Schans VA, ter Horst P, Smits JF.

Trends Pharmacol Sci. 2008 Apr;29(4):175-80. doi: 10.1016/j.tips.2008.01.003. Epub 2008 Mar 14. Review.

PMID:
18342376
44.

Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: implications for FXIII therapy and antithrombin use in myocardial infarction.

Nahrendorf M, Aikawa E, Figueiredo JL, Stangenberg L, van den Borne SW, Blankesteijn WM, Sosnovik DE, Jaffer FA, Tung CH, Weissleder R.

Eur Heart J. 2008 Feb;29(4):445-54. doi: 10.1093/eurheartj/ehm558.

PMID:
18276618
45.

Interruption of Wnt signaling attenuates the onset of pressure overload-induced cardiac hypertrophy.

van de Schans VA, van den Borne SW, Strzelecka AE, Janssen BJ, van der Velden JL, Langen RC, Wynshaw-Boris A, Smits JF, Blankesteijn WM.

Hypertension. 2007 Mar;49(3):473-80. Epub 2007 Jan 8.

PMID:
17210832
46.

The inner nuclear membrane protein emerin regulates beta-catenin activity by restricting its accumulation in the nucleus.

Markiewicz E, Tilgner K, Barker N, van de Wetering M, Clevers H, Dorobek M, Hausmanowa-Petrusewicz I, Ramaekers FC, Broers JL, Blankesteijn WM, Salpingidou G, Wilson RG, Ellis JA, Hutchison CJ.

EMBO J. 2006 Jul 26;25(14):3275-85. Epub 2006 Jul 20.

47.

Alterations in mouse cardiac proteome after in vivo myocardial infarction: permanent ischaemia versus ischaemia-reperfusion.

De Celle T, Vanrobaeys F, Lijnen P, Blankesteijn WM, Heeneman S, Van Beeumen J, Devreese B, Smits JF, Janssen BJ.

Exp Physiol. 2005 Jul;90(4):593-606. Epub 2005 Apr 15.

48.

Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy.

Schroen B, Heymans S, Sharma U, Blankesteijn WM, Pokharel S, Cleutjens JP, Porter JG, Evelo CT, Duisters R, van Leeuwen RE, Janssen BJ, Debets JJ, Smits JF, Daemen MJ, Crijns HJ, Bornstein P, Pinto YM.

Circ Res. 2004 Sep 3;95(5):515-22. Epub 2004 Jul 29.

PMID:
15284191
49.

Long-term structural and functional consequences of cardiac ischaemia-reperfusion injury in vivo in mice.

De Celle T, Cleutjens JP, Blankesteijn WM, Debets JJ, Smits JF, Janssen BJ.

Exp Physiol. 2004 Sep;89(5):605-15. Epub 2004 Jul 15.

50.

The wnt-frizzled cascade in cardiovascular disease.

van Gijn ME, Daemen MJ, Smits JF, Blankesteijn WM.

Cardiovasc Res. 2002 Jul;55(1):16-24. Review. No abstract available.

PMID:
12062705

Supplemental Content

Loading ...
Support Center